Drugs / SLP-HPV-01®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01923116 | Aug 2013 → Jun 2017 | HIV infectious disease, intraepithelial neoplasia | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLP-HPV-01 | “therapeutic vaccination with a synthetic long-peptide vaccine SLP-HPV-01® , consisting of a mix of long peptides from the HPV-16 viral oncoproteins E6 and E7” NCT01923116 ↗ |
| Modality | Vaccine | “synthetic long-peptide vaccine SLP-HPV-01®” NCT01923116 ↗ |
| Route | Other | “administered intradermally” NCT01923116 ↗ |